Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Her2 and Ki67 Biomarkers Predict Recurrence of Ductal Carcinoma in Situ

Her2 and Ki67 Biomarkers Predict Recurrence of Ductal Carcinoma in Situ RESEARCH ARTICLE Her2 and Ki67 Biomarkers Predict Recurrence of Ductal Carcinoma in Situ James E. Davis, MD, Barbara Nemesure, PhD, Saira Mehmood, MD, Vipul Nayi, MD, Stephanie Burke, BS, Sabrina R. Brzostek, MD, PhD, and Meenakshi Singh, MD uctal carcinoma in situ (DCIS) is a nonobligate Background: A subset of patients with ductal carcinoma in situ Dprecursor of invasive breast cancer with an incidence (DCIS) experience recurrence or progression to invasive cancer. which has sharply increased from 1.87 per 100,000 in the Current clinical practice is not reliably guided by DCIS re- early 1970s to 32.5 per 100,000 by the early 2000s. DCIS currence prediction, although recurrence risk for invasive breast is now estimated to account for 20% of breast carcinomas cancer can now be assessed. We analyzed a panel of biomarkers detected by mammography. Current treatment guidelines (estrogen receptor, Her2, Ki67, p53, cyclin D1, COX-2, cav- recommend a balance between minimizing the risk of eolin-1, survivin, and PPAR-g) and DCIS histologic and clinical local recurrence and/or progression to invasive disease features to determine associations with DCIS recurrence. versus using breast-conserving surgery with or without radiation therapy and with or without hormonal ther- Materials and Methods: Seventy DCIS cases http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Applied Immunohistochemistry & Molecular Morphology Wolters Kluwer Health

Her2 and Ki67 Biomarkers Predict Recurrence of Ductal Carcinoma in Situ

Applied Immunohistochemistry & Molecular Morphology , Volume Publish Ahead of Print – Aug 1, 2015

Loading next page...
 
/lp/wolters-kluwer-health/her2-and-ki67-biomarkers-predict-recurrence-of-ductal-carcinoma-in-019wSGTpvY
Copyright
Copyright © 2015 Wolters Kluwer Health, Inc. All rights reserved.
ISSN
1541-2016
DOI
10.1097/PAI.0000000000000223
pmid
26317313
Publisher site
See Article on Publisher Site

Abstract

RESEARCH ARTICLE Her2 and Ki67 Biomarkers Predict Recurrence of Ductal Carcinoma in Situ James E. Davis, MD, Barbara Nemesure, PhD, Saira Mehmood, MD, Vipul Nayi, MD, Stephanie Burke, BS, Sabrina R. Brzostek, MD, PhD, and Meenakshi Singh, MD uctal carcinoma in situ (DCIS) is a nonobligate Background: A subset of patients with ductal carcinoma in situ Dprecursor of invasive breast cancer with an incidence (DCIS) experience recurrence or progression to invasive cancer. which has sharply increased from 1.87 per 100,000 in the Current clinical practice is not reliably guided by DCIS re- early 1970s to 32.5 per 100,000 by the early 2000s. DCIS currence prediction, although recurrence risk for invasive breast is now estimated to account for 20% of breast carcinomas cancer can now be assessed. We analyzed a panel of biomarkers detected by mammography. Current treatment guidelines (estrogen receptor, Her2, Ki67, p53, cyclin D1, COX-2, cav- recommend a balance between minimizing the risk of eolin-1, survivin, and PPAR-g) and DCIS histologic and clinical local recurrence and/or progression to invasive disease features to determine associations with DCIS recurrence. versus using breast-conserving surgery with or without radiation therapy and with or without hormonal ther- Materials and Methods: Seventy DCIS cases

Journal

Applied Immunohistochemistry & Molecular MorphologyWolters Kluwer Health

Published: Aug 1, 2015

There are no references for this article.